A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors - Eigentler, Thomas; Krauss, Juergen; Schreiber, Jutta; Weishaupt, Carsten; Terheyden, Patrick; Heinzerling, Lucie; Mohr, Peter; Weide, Benjamin; Ochsenreither, Sebastian; Becker, Juergen; Bauernfeind, Franz-Georg; Brossart, Peter; et al. (JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019)
CRIS-Team WoS Importer:2019-11-29